Objective: To describe the dynamics of copeptin in open cardiac surgery during the perioperative course.
Conclusions:
Regardless of cardiac surgical procedure and perioperative course all patients had an early significant raise of copeptin concentrations generally peaking at weaning from CBP or upon arrival in ICU. Among patients with normal copeptin concentration preoperatively and uneventful course, the postoperative copeptin concentrations decreased to normal values within 3-4 days after cardiac surgery. Furthermore, the restricted "normal cohort" generally tended to display lower levels of copeptin concentration postoperatively. Further studies may evaluate whether copeptin can be a tool in identifying risk patients in cardiac surgery.
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Background
Vasopressin (AVP) is secreted into the circulation from the hypothalamic gland as a response to changes in plasma osmolarity, blood volume and reduced cardiac output [1] [2] [3] . Increased secretion of AVP is also seen as a response to trauma and oxidative stress 4, 5 . AVP acts in the kidney, heart and blood vessels to generate vasoconstriction and influencing afterload. AVP concentration is affected in a variety of endocrinological and circulatory disorders 2 .
As a consequence of the central role for AVP in regulation of hemodynamics, there has been several studies on AVP relating to vasodilatory shock and vasoplegia. Septic shock has been described as a relative AVP deficiency and it has been speculated that conditions with severe vasoplegic syndrome are linked to arginine-vasopressin dysfunction 6, 7 . This has made AVP into an important tool in treating patients with both septic and non-septic critical vasoplegic conditions 6 . In this perspective it´s important to be able to measure AVP in clinical settings and relate to clinical outcome.
However, AVP measurements have been inconsistent due to the fact that 90 % of AVP is bound to platelets, has short half-life and is a temperature sensitive blood sample 2, 8 . Overall this has made measurement of AVP difficult to bring into clinical routine. Copeptin, the C-terminal part of pre-proAVP, is a more stable peptide both in plasma and during storage, and thus easier to measure. As copeptin is secreted in equimolar amounts as AVP it can accordingly be used as a surrogate for AVP release 2, 8 .
Copeptin has been studied as a biomarker in cardiology and proved to be prognostic in heart failure and discriminative in acute ischemic heart disease [9] [10] [11] . The release pattern of copeptin has been described in patients with acute coronary syndrome and acute myocardial infarction 12 . A previous study on patients undergoing transcoronary ablation of septal hypertrophy showed that copeptin is released quickly within 30 minutes after induction of myocardial infarction and maximum after 90 minutes and returns to baseline within 24 hours 13 . A similar pattern of copeptin response was seen in a study on patients undergoing radiofrequency ablation for atrial fibrillation 14 .
In cardiac surgery AVP and copeptin are sparsely studied. Earlier studies on AVP and copeptin have shown a significant early rise during cardiopulmonary bypass 15, 16 . In another study by Jochberger et al it was shown that AVP and copeptin decline during the first days after uncomplicated coronary artery bypass surgery (CABG) 17 . That study also showed that patients with vasodilatory shock after cardiac surgery had elevated concentrations for the first 7 days after surgery and not so prominent peak value 17 .
In order to further understand copeptin as a prognostic tool and guidance in cardiac surgery, it is essential to define the temporal release kinetics during the whole perioperative course. To the best of our knowledge, the release pattern of copeptin for the whole perioperative course in cardiac surgery has not previously been described. Therefore, the aim of this study was to analyse the dynamics of copeptin in open cardiac surgery with CPB during the perioperative course from preoperative to day 6 postoperatively, both in an unselected cohort of patients and in a restricted cohort of patients with normal preoperative copeptin and uneventful perioperative course.
Methods

Patients and design
Between February to September 2015 we prospectively included 20 patients planned for various cardiac surgical procedures, Supplementary file 1 and Table 1 . The study was conducted as a prospective longitudinal observational study performed at one single cardiothoracic department, at a university hospital.
Restricted cohort criteria:
From the whole cohort one restricted cohort of patients was analysed separately as a "normal No stroke defined as a focal neurological deficit persisting for more than 24 hours with signs of cerebral injury on CT-scan.
Blood sampling and data collection
Blood samples were taken both in conjunction with the standard clinical practice and as specific analysis for the study. Copeptin samples were taken on the day before surgery, on the day of surgery in the operating room (OR) before induction of anaesthesia, at weaning from CPB, upon arrival in intensive care unit (ICU), 8 hours postoperatively, on the morning first day after surgery and thereafter every morning until postoperatively day 6. A total of 11 copeptin samples were collected in each patient. Samples of mixed venous oxygen saturation, SvO 2 upon arrival in ICU were drawn from an intraoperatively surgically placed epidural catheter placed through the right ventricular outflow tract. This procedure is standardized at our institution and previously described 18 .
Of the total 220 copeptin samples, 13 samples were missed ( 
Clinical management
Premedication and induction/maintenance of anaesthesia were standardized. After an overnights fast, patients were premedicated with oxazepam 5-10 mg orally (PO), and paracetamol 1 g PO.
General anaesthesia was induced with thiopental and fentanyl intravenously (IV). Rocuronium bromide IV was used for neuromuscular block. Anaesthesia was maintained with isoflurane and intermittent fentanyl, and the patients were normoventilated. Patients were managed surgically with standard techniques for cannulation and CPB. The CPB was performed with a roller pump and a membrane oxygenator (coated) with integrated arterial filter and a combined cardiotomy/venous reservoir. Before cannulation heparine was administered IV. The extracorporeal circuit was primed with 1500mL of Ringer, with 200 mL of Mannitol. In all patients but one (HeartMate II-Left ventricular assist device, LVAD) aortic cross clamp was used. Cardiac protection was achieved with cold blood cardioplegia.
Statistics
The emerging data are presented as mean ± SD, median and interquartile range (IQR) or proportions as appropriate. Analysis for the copeptin release curve was done using Friedmans ANOVA. Wilcoxons test with Bonferroni correction was used for analysis of differences between levels within the copeptin release curve. Bonferroni correction was adjusted based on 10 comparisons within the release curve. We considered differences statistically significant if p<0.05
(for the Friedman test p<0.05 is equal to p<0.005 with Bonferroni correction). Statistical analyses were made with Statistica ® version 12 (StatSoft, Inc., Tulsa, OK, USA).
Ethics
After written informed consent the patients were enrolled into the study. The study was performed according to the Helsinki Declaration of Human Rights. The study was approved by the Regional Ethical Review Board in Linköping (EPN 2014/50-31)
Results
Baseline data
The mean age in the total study population (n=20) was 71 ± 8 years and 20 % were females.
Preoperative riskscoring model EuroSCORE II 19 was median 1.7 (IQR,1.3-2.7) and preoperative NT-proBNP was 740 ng/L (IQR,175-1200). The mean CPB time was 91 ± 29 minutes. Inhospital stay was 9 days (IQR, [8] [9] [10] [11] [12] [13] [14] . There were no in-hospital or 30-day mortality. Detailed data are presented in Table 1 and 2.
Temporal release pattern of copeptin -total study population (n=20)
The preoperative copeptin concentration in the total study population was 7.0 pmol/L (IQR;3.1-11.0) on the day before surgery and no significant difference at induction in the OR 6.2 pmol/L (IQR;3.6-9.9). There was a significant raise with median peak at weaning from CPB 235 pmol/L (IQR;96-342, p<0.001). There was a significant decrease of copeptin concentration between weaning from CPB and postoperative day 1 (235 vs 37 pmol/L, p=0.0015). Although copeptin decreased postoperatively to median levels between 10-14 pmol/L during postoperative day 3-6 there were still significantly higher values during this postoperative period compared to preoperatively (p<0.005), Table 1 8 days (7) (8) (9) (10) (11) . At revisit to a cardiologist approximately 2 months after surgery all these patients were in adequate recovery. Detailed data presented in Table 1 
Discussion
Our main findings in this study were that all patients, regardless type of cardiac surgery, had a similar kinetic release curve with an early major raise of the copeptin concentrations generally The peak concentration of copeptin in our study were, among most patients, already at weaning from CPB or upon arrival in ICU indicating that copeptin reacts very fast to the trauma created by cardiac surgery and CPB. The concentrations of copeptin declined thereafter significantly on day 1 postoperatively, especially among patients with an uncomplicated course.
It is reasonable to believe that in patients with a normal preoperative copeptin concentration and adequate inflammatory response without perioperative complications, copeptin concentrations will return to normal levels when the surgical trauma is ended and vasoplegia declines. This response is illustrated by patient no 16 in Supplementary file 1, that upon arrival in ICU displayed the highest level of copeptin, 1067pmol/L. This patient had a major venous bleeding peroperatively before CPB and was described in the chart by the anesthesiologist as hypovolemic. This patient also was recorded with the lowest blood pressure > 5 minutes during CPB (40 mmHg). This patient seems to have had an adequate response to severe hemodynamic stress with high postoperative copeptin levels early postoperatively, but returned to almost normal copeptin concentration on day 3 postoperatively (12 pmol/L), and normal levels on day 5 postoperatively (7.5 pmol/L) Table 1 . In contrast, none of the patients with preoperative elevated copeptin concentrations independent of perioperative course had normal levels of copeptin concentration during the 6 days of postoperative copeptin measurement.
Oxidative stress seems to have an important role as modulator in ischemic heart disease and remodelling in heart failure 21 . Markers for oxidative stress has been shown to correlate to activity in atherosclerotic disease 21 . Furthermore it has been shown that CPB induce a substantial amount of free radicals, reactive oxygen species 4, 22 . It has been speculated that oxidative stress during cardiac surgery may aggravate impairment of myocytes and inflammatory response which could aggravate vasoplegia 4 . One may argue that patients with high preoperative concentrations of copeptin are subject to a greater oxidative stress before surgery, and further speculate that this increased oxidative stress is one of the major causes for prolonged high concentrations of copeptin in the perioperative course. Either way, copeptin proves as a fast and sensitive biomarker for the level of trauma and circulatory events in the setting of cardiac surgery and might act as an early warning sign to disturbances in the hemodynamic situation. The role of lack of pulsatile perfusion on the copeptin levels is unclear.
Since the introduction of copeptin as a stable biomarker and surrogate for AVP, studies have proven the prognostic value of copeptin in cardiovascular disease. Also it has been shown that combining copeptin with other biomarkers such as natriuretic peptides and troponins have made the discriminative value even stronger in identifying patients with heart failure and acute ischemic heart disease 9, 11 .
Copeptin is sparsely studied in cardiac surgery, especially as a prognostic tool. Based on the experience from use of copeptin in cardiology and the fact that AVP have a central role in the regulation of vasoplegia its reasonable to believe that copeptin could be a valuable tool as prognostic biomarker in cardiac surgery. In contrast to copeptin, natriuretic peptides have been well established as prognostic biomarker in cardiac surgery, and have been integrated in clinical use among cardiac surgery patients 23, 24 . The perioperative release pattern of copeptin in our study differs to natriuretic peptides. In uncomplicated cardiac surgery patients NT-proBNP raise until day 3-4 postoperatively and thereafter start to decline 25 . This difference in temporal release curves may illustrate the fact that NT-proBNP and copeptin are secreted as respons to different aspects of stress during heart surgery. NT-proBNP is mainly released into the plasma as a response to increased myocyte wall tension and ischemia 26 , whereas copeptin is mainly released into the plasma as a response to changes in osmolarity and blood volume, but also as a response to increased oxidative stress 5, 21 .
Overall, the release pattern of copeptin in this study is quite clear. The presentation of data in the study is strictly descriptive and don´t allow any conclusive evaluation of copeptin as predictive value for identifying risk patients. However, when analysing the data from the individual patients presented in the supplementary file 1 some aspects can be addressed. There are indications that patients with preoperative elevated concentrations of copeptin and/or complications during the perioperative course have elevated concentrations of copeptin early postoperatively as well as for a prolonged period postoperatively. Still, it is unclear how copeptin concentrations in cardiac surgery can support prognostic evaluation. It is reasonable to speculate that copeptin could have a potential role as prognostic complement to established scoring systems such as EuroSCORE II
and biochemical markers such as natriuretic peptides. Further studies should focus on a possible prognostic potential regarding copeptin concentrations in cardiac surgery and also discriminate between different groups of patients, such as ischemic heart disease and valve disease.
Limitations of the study
We 
Conclusions
In conclusion this study shows, that regardless of cardiac surgical procedure and perioperative course all patients had an early major raise of copeptin concentrations generally peaking at weaning from CBP or upon arrival in ICU. In patients with normal copeptin concentration preoperatively and uneventful course, the postoperative copeptin concentrations have decreased to normal values within 3-4 days after cardiac surgery. Furthermore, this restricted "normal cohort" generally tended to display lower levels of copeptin concentration postoperatively. These observations indicate that copeptin may have potential as a prognostic tool in cardiac surgery.
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